Literature DB >> 30798431

Acromegaly can be cured by first-line pasireotide treatment?

Sabrina Chiloiro1, Antonella Giampietro1, Antonio Bianchi1, Tommaso Tartaglione2, Chiara Bima1, Maria Gabriella Vita3, Maurizio Spinello4, Alfredo Pontecorvi1, Laura De Marinis5.   

Abstract

Entities:  

Year:  2019        PMID： 30798431     DOI： 10.1007/s12020-019-01874-4

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  11 in total

1.  Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.

Authors:  Mônica R Gadelha; Marcello D Bronstein; Thierry Brue; Mihail Coculescu; Maria Fleseriu; Mirtha Guitelman; Vyacheslav Pronin; Gérald Raverot; Ilan Shimon; Kayo Kodama Lievre; Juergen Fleck; Mounir Aout; Alberto M Pedroncelli; Annamaria Colao
Journal:  Lancet Diabetes Endocrinol       Date:  2014-09-24       Impact factor: 32.069

Review 2.  Expert consensus document: A consensus on the medical treatment of acromegaly.

Authors:  Andrea Giustina; Philippe Chanson; David Kleinberg; Marcello D Bronstein; David R Clemmons; Anne Klibanski; Aart J van der Lely; Christian J Strasburger; Steven W Lamberts; Ken K Y Ho; Felipe F Casanueva; Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2014-02-25       Impact factor: 43.330

3.  Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control.

Authors:  Ilan Shimon; Wolfgang Saeger; Luiz Eduardo Wildemberg; Monica R Gadelha
Journal:  Hormones (Athens)       Date:  2017-01       Impact factor: 2.885

4.  Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study.

Authors:  Shigeyuki Tahara; Mami Murakami; Tomomi Kaneko; Akira Shimatsu
Journal:  Endocr J       Date:  2017-07-08       Impact factor: 2.349

Review 5.  Management of endocrine disease: pituitary tumour apoplexy.

Authors:  Cristina Capatina; Warrick Inder; Niki Karavitaki; John A H Wass
Journal:  Eur J Endocrinol       Date:  2014-12-01       Impact factor: 6.664

6.  Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly.

Authors:  Jan-Shun Chang; Ham-Min Tseng; Tien-Chun Chang
Journal:  J Formos Med Assoc       Date:  2016-04-23       Impact factor: 3.282

7.  Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.

Authors:  Donato Iacovazzo; Eivind Carlsen; Francesca Lugli; Sabrina Chiloiro; Serena Piacentini; Antonio Bianchi; Antonella Giampietro; Marilda Mormando; Andrew J Clear; Francesco Doglietto; Carmelo Anile; Giulio Maira; Libero Lauriola; Guido Rindi; Federico Roncaroli; Alfredo Pontecorvi; Márta Korbonits; Laura De Marinis
Journal:  Eur J Endocrinol       Date:  2015-11-19       Impact factor: 6.664

8.  Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study.

Authors:  Maria Fleseriu; Elisha Rusch; Eliza B Geer
Journal:  Endocrine       Date:  2016-11-28       Impact factor: 3.633

9.  Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.

Authors:  Michael Sheppard; Marcello D Bronstein; Pamela Freda; Omar Serri; Laura De Marinis; Luciana Naves; Liudmila Rozhinskaya; Karina Hermosillo Reséndiz; Matthieu Ruffin; YinMiao Chen; Annamaria Colao
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

10.  Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.

Authors:  Marcello D Bronstein; Maria Fleseriu; Sebastian Neggers; Annamaria Colao; Michael Sheppard; Feng Gu; Chiung-Chyi Shen; Mônica Gadelha; Andrew J Farrall; Karina Hermosillo Reséndiz; Matthieu Ruffin; YinMiao Chen; Pamela Freda
Journal:  BMC Endocr Disord       Date:  2016-04-02       Impact factor: 2.763
View more
  2 in total

Review 1.  Acromegaly in the elderly patients.

Authors:  Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2020-02-14       Impact factor: 3.633

2.  Somatostatin receptors in normal and acromegalic somatotroph cells: the U-turn of the clinician to immunohistochemistry report - a review.

Authors:  Nina Ionovici; Mara Carsote; Dana Cristina Terzea; Anca Mihaela Predescu; Anne Marie Rauten; Mihaela Popescu
Journal:  Rom J Morphol Embryol       Date:  2020 Apr-Jun       Impact factor: 1.033
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.